Eurizon Capital SGR S.p.A. Buys 161,643 Shares of Johnson & Johnson $JNJ

Eurizon Capital SGR S.p.A. raised its stake in Johnson & Johnson (NYSE:JNJ) by 8.7% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,022,406 shares of the company’s stock after buying an additional 161,643 shares during the period. Johnson & Johnson makes up approximately 1.4% of Eurizon Capital SGR S.p.A.’s holdings, making the stock its 12th largest holding. Eurizon Capital SGR S.p.A. owned about 0.08% of Johnson & Johnson worth $536,956,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Werba Rubin Papier Wealth Management raised its position in shares of Johnson & Johnson by 7.2% during the 3rd quarter. Werba Rubin Papier Wealth Management now owns 4,627 shares of the company’s stock worth $1,225,000 after purchasing an additional 310 shares during the last quarter. Van Strum & Towne Inc. lifted its stake in Johnson & Johnson by 1.0% in the 3rd quarter. Van Strum & Towne Inc. now owns 45,074 shares of the company’s stock valued at $11,933,000 after buying an additional 442 shares in the last quarter. Austin Wealth Management LLC grew its holdings in Johnson & Johnson by 10.8% during the 3rd quarter. Austin Wealth Management LLC now owns 1,972 shares of the company’s stock valued at $506,000 after buying an additional 193 shares during the last quarter. CENTRAL TRUST Co grew its holdings in Johnson & Johnson by 0.4% during the 3rd quarter. CENTRAL TRUST Co now owns 115,152 shares of the company’s stock valued at $30,485,000 after buying an additional 449 shares during the last quarter. Finally, Artemis Wealth Advisors LLC increased its position in Johnson & Johnson by 44.7% during the third quarter. Artemis Wealth Advisors LLC now owns 2,315 shares of the company’s stock worth $613,000 after buying an additional 715 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 15,000 shares of the firm’s stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $263.36, for a total value of $3,950,400.00. Following the sale, the executive vice president directly owned 194,451 shares of the company’s stock, valued at approximately $51,210,615.36. This trade represents a 7.16% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Timothy Schmid sold 33,597 shares of the company’s stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the transaction, the executive vice president directly owned 25,447 shares of the company’s stock, valued at approximately $6,991,308.78. This represents a 56.90% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson News Roundup

Investors following JNJ have been watching these news items:

• Neutral Sentiment: State Street’s Health Care SPDR added J&J shares on Nov. 10 as part of a broader increase across all of the fund’s holdings. The purchase provides an institutional-demand datapoint but was not specific to J&J. State Street Health Care SPDR adds Johnson & Johnson
• Negative Sentiment: A Massachusetts jury awarded $3.3 million to the family of a woman who developed mesothelioma after using J&J talc-based baby powder. The award adds to ongoing talc-related litigation exposure. Massachusetts woman’s family awarded $3.3 million against Johnson & Johnson
• Negative Sentiment: Pomerantz LLP said it is investigating potential claims on behalf of J&J investors. The announcement does not establish wrongdoing or the outcome of any claims, but adds another legal headline for investors to monitor. Pomerantz law firm investigates claims on behalf of J&J investors

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on JNJ shares. Sanford C. Bernstein set a $270.00 price target on Johnson & Johnson in a report on Thursday, October 15th. Raymond James Financial set a $280.00 price objective on Johnson & Johnson in a research note on Monday, August 3rd. Bank of America reiterated a “neutral” rating and set a $278.00 price objective on shares of Johnson & Johnson in a research report on Tuesday, September 29th. Morgan Stanley cut their target price on shares of Johnson & Johnson from $294.00 to $292.00 and set an “overweight” rating for the company in a research note on Thursday, October 15th. Finally, Wall Street Zen lowered shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Saturday, August 1st. One research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and eight have assigned a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $275.92.

Johnson & Johnson Stock Up 1.2%

Shares of NYSE JNJ opened at $283.69 on Friday. The firm has a market cap of $682.93 billion, a P/E ratio of 42.98, a price-to-earnings-growth ratio of 2.77 and a beta of 0.22. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.74 and a current ratio of 1.02. Johnson & Johnson has a 1 year low of $193.45 and a 1 year high of $286.08. The firm’s 50 day moving average price is $266.83 and its 200 day moving average price is $249.54.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, October 13th. The company reported $2.59 earnings per share for the quarter, beating the consensus estimate of $2.53 by $0.06. Johnson & Johnson had a return on equity of 31.64% and a net margin of 16.20%. The company had revenue of $25.40 billion during the quarter, compared to the consensus estimate of $25.38 billion. During the same period in the previous year, the firm posted $2.80 EPS. Johnson & Johnson’s revenue was up 5.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. As a group, sell-side analysts anticipate that Johnson & Johnson will post 11.12 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 8th. Investors of record on Tuesday, November 24th will be paid a $1.34 dividend. This represents a $5.36 annualized dividend and a yield of 1.9%. The ex-dividend date is Tuesday, November 24th. Johnson & Johnson’s dividend payout ratio is presently 81.21%.

Johnson & Johnson Company Profile

Johnson & Johnson is a global healthcare company that develops and sells prescription medicines and medical technologies. Its business is organized around two segments: Innovative Medicine and MedTech. Innovative Medicine develops treatments in areas including oncology, immunology, neuroscience, cardiovascular and metabolic disease, and pulmonary hypertension. MedTech provides products and technologies for fields such as surgery, orthopedics, and vision care. Founded in 1886, Johnson & Johnson serves patients and healthcare professionals in markets around the world.